Principal Financial Group Inc. trimmed its position in shares of Novo Nordisk A/S (NYSE:NVO) by 17.7% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 9,320 shares of the company’s stock after selling 2,000 shares during the quarter. Principal Financial Group Inc.’s holdings in Novo Nordisk A/S were worth $430,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Northern Trust Corp boosted its holdings in Novo Nordisk A/S by 6.8% during the 4th quarter. Northern Trust Corp now owns 2,319,391 shares of the company’s stock valued at $106,855,000 after acquiring an additional 148,443 shares during the period. Douglas Lane & Associates LLC purchased a new position in Novo Nordisk A/S during the 4th quarter valued at about $378,000. Brookstone Capital Management boosted its holdings in Novo Nordisk A/S by 8.0% during the 4th quarter. Brookstone Capital Management now owns 7,221 shares of the company’s stock valued at $333,000 after acquiring an additional 535 shares during the period. Wambolt & Associates LLC purchased a new position in Novo Nordisk A/S during the 4th quarter valued at about $298,000. Finally, First Hawaiian Bank boosted its holdings in Novo Nordisk A/S by 4.4% during the 4th quarter. First Hawaiian Bank now owns 35,162 shares of the company’s stock valued at $1,620,000 after acquiring an additional 1,482 shares during the period. Institutional investors own 7.06% of the company’s stock.

NVO has been the subject of a number of research analyst reports. BNP Paribas started coverage on Novo Nordisk A/S in a report on Tuesday, January 29th. They set an “outperform” rating for the company. Barclays reiterated a “sell” rating on shares of Novo Nordisk A/S in a research note on Tuesday, February 5th. Morgan Stanley started coverage on Novo Nordisk A/S in a research note on Friday, February 1st. They issued an “equal weight” rating for the company. Handelsbanken cut Novo Nordisk A/S from a “buy” rating to an “accumulate” rating and set a $48.61 price objective for the company. in a research note on Monday, February 4th. Finally, Zacks Investment Research upgraded Novo Nordisk A/S from a “hold” rating to a “strong-buy” rating and set a $56.00 price objective for the company in a research note on Tuesday, February 5th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and seven have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $52.31.

Shares of NVO opened at $48.10 on Tuesday. The stock has a market capitalization of $118.24 billion, a PE ratio of 19.09, a P/E/G ratio of 2.14 and a beta of 0.60. Novo Nordisk A/S has a 1 year low of $41.23 and a 1 year high of $52.83.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Friday, February 1st. The company reported $0.54 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.57 by ($0.03). The company had revenue of $4.55 billion during the quarter, compared to analysts’ expectations of $4.36 billion. Novo Nordisk A/S had a net margin of 34.67% and a return on equity of 80.45%. As a group, sell-side analysts expect that Novo Nordisk A/S will post 2.47 earnings per share for the current fiscal year.

WARNING: This article was first reported by Watch List News and is the property of of Watch List News. If you are viewing this article on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://www.watchlistnews.com/novo-nordisk-a-s-nvo-shares-sold-by-principal-financial-group-inc/2982158.html.

Novo Nordisk A/S Profile

Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases.

Recommended Story: Beta

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO).

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.